Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
FDA grants accelerated approval to zongertinib for HER2 TKD-Mutated Non-Squamous NSCLC
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options
Subscribe To Our Newsletter & Stay Updated
